Loibl et al. reported the results of a next generation sequencing analysis that was carried out in the neoadjuvant GepurSepto trial; in this study, 851 pretherapeutic formalin-fixed samples were sequenced using a breast cancer-specific hotspot panel of 24 genes (allowing to screen the most relevant mutation and CNA events occurring in this tumor), performing a stratified analysis according to the luminal, HER2-positive, and TNBC subtypes. This evidence concerns the gene ERBB2 and breast cancer.